Targeted Drug Delivery

A special issue of Bioengineering (ISSN 2306-5354).

Deadline for manuscript submissions: closed (18 August 2018) | Viewed by 8353

Special Issue Editor


E-Mail Website
Guest Editor
School of Biological Sciences, Louisiana Tech University, Ruston, LA 71272, USA
Interests: cancer biomaterials; bioengineering; implant design; surface modification; targeted drug delivery; tissue engineering; 3D printing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The clinically significant impact of targeted drug delivery lies in the ability to target a drug or drug carrier to minimize the impact of drug-originated systemic toxic effects. Nanotechnology-based biomedical approaches hold great promise for providing targeted therapies that limit or reduce side effects, improve patient compliance, reduce patient costs, the length of hospital stays and improve quality of life. During the last several decades, controlled drug and multidrug delivery technology have advanced significantly, leading to the development of sophisticated drug delivery systems. Although still in its infancy, an intensive effort is being directed towards the development of more efficient, functional, and safe drug delivery systems. Oral and transdermal drug delivery systems routinely deliver drugs over a twenty-four-hour period substantially improving drug efficacy and minimizing side effects. Implantable systems can provide drugs locally for months, even years. Targeted delivery can be actively or passively achieved using a variety of fabrication methods and applied either as an active target system requiring conjugation of a therapeutic agent to a carrier system through tissue or cell-specific ligand. Passive targeting, in contrast, integrates the therapeutic agent into a macromolecule or nanoparticle that passively reaches the target organ. While significant advances have been made, there are still areas where substantial improvements need to be made to reach the next level of clinical relevance. The focus of this Special Issue is the development of novel drug delivery systems that offer prolonged release kinetics and long persistence at the target site while simultaneously reducing unwanted side effects.

Examples of manuscript research areas requested:

1]. Drugs encapsulated in nanoparticles or drugs coupled to macromolecules with a bound targeting agent

2]. Contact-facilitated drug delivery using liposomes and binding or interaction with the targeted cell membrane.

3]. Soluble polymers or biodegradable microsphere polymers (synthetic and natural) that target delivery of bioactive factors or drugs

4]. Multi-composite drug delivery system such as metal NP

5]. Medical devices, such as catheters or sutures, that incorporate nanoparticles to the target organ or tissues.

Prof. Dr. David K. Mills
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 3200 KiB  
Review
Integrin-Mediated Delivery of Drugs and Nucleic Acids for Anti-Angiogenic Cancer Therapy: Current Landscape and Remaining Challenges
by Poulami Majumder
Bioengineering 2018, 5(4), 76; https://doi.org/10.3390/bioengineering5040076 - 20 Sep 2018
Cited by 17 | Viewed by 7358
Abstract
Angiogenesis, sprouting of new blood vessels from pre-existing vasculatures, plays a critical role in regulating tumor growth. Binding interactions between integrin, a heterodimeric transmembrane glycoprotein receptor, and its extracellular matrix (ECM) protein ligands govern the angiogenic potential of tumor endothelial cells. Integrin receptors [...] Read more.
Angiogenesis, sprouting of new blood vessels from pre-existing vasculatures, plays a critical role in regulating tumor growth. Binding interactions between integrin, a heterodimeric transmembrane glycoprotein receptor, and its extracellular matrix (ECM) protein ligands govern the angiogenic potential of tumor endothelial cells. Integrin receptors are attractive targets in cancer therapy due to their overexpression on tumor endothelial cells, but not on quiescent blood vessels. These receptors are finding increasing applications in anti-angiogenic therapy via targeted delivery of chemotherapeutic drugs and nucleic acids to tumor vasculatures. The current article attempts to provide a retrospective account of the past developments, highlight important contemporary contributions and unresolved set-backs of this emerging field. Full article
(This article belongs to the Special Issue Targeted Drug Delivery)
Show Figures

Figure 1

Back to TopTop